Key Takeaways for Pfizer Stock as of September 2026
- CEO Albert Bourla told analysts Pfizer will maintain its dividend through “even the most stretched scenarios,” with growth resuming once the 2028 patent-cliff period passes.
- Pfizer’s dividend sat at $0.43 per share as of June 2026.
- A payout ratio of -988.31% looks alarming next to a 6.30% yield, but the negative reading traces to a single-quarter GAAP loss, not a cash shortfall.
- TIKR’s mid-case valuation model puts Pfizer stock’s target price at $32 by March 2032, a 15% total return worth 3% annualized.
Bourla Draws a Hard Line: Pfizer Stock’s Dividend Holds No Matter How Stretched the Scenario
Pfizer (PFE) stock carried a blunt message out of the company’s second-quarter 2026 earnings call: the dividend is not up for debate. An analyst asked what might force a cut, and CEO Albert Bourla left no room for interpretation.
“We feel extremely confident that… we will be able to maintain our dividend,” Bourla said, adding that the payout would resume growing once the loss-of-exclusivity period ends in 2028.
Incoming interim CFO Cecile Guegan echoed that framing earlier on the call, telling investors Pfizer intends to keep “maintaining and over the long term, growing the dividend” as part of its capital allocation approach. That commitment sits on top of $4.9 billion Pfizer already returned to shareholders through its quarterly dividend in the first half of 2026, alongside $5.5 billion invested in internal and external R&D over the same stretch.
Guegan also raised full-year revenue guidance by $500 million at the midpoint, to a range of $60.5 billion to $62.5 billion, even after cutting COVID-19 revenue expectations from $5 billion to $4 billion. Adjusted diluted EPS guidance held at $2.80 to $3.00, a range that now absorbs a $0.10 hit tied to the $650 million upfront payment for the Innovent Biologics transaction that closed in July.
The quarter’s GAAP results told a rougher story. Pfizer reported a loss per share of $0.04, driven by $4.3 billion in noncash impairments after SV missed its primary survival endpoint in second-line lung cancer and Oxbryta’s revenue forecast was pulled following FDA discussions. Guegan said leverage ended the quarter at 2.7x and is expected to hold near that level, or rise modestly, through the loss-of-exclusivity transition.
Pfizer Stock’s Payout Ratio Swings Negative While the Dividend Itself Holds Firm at $0.43
Pfizer’s quarterly dividend stood at $0.43 per share as of June 2026, the same level paid in each of the two prior quarters. That figure climbed from $0.42 in September 2024, with two sharply higher prints along the way, $0.84 in December 2024 and $0.86 in December 2025, before settling back to $0.43 each time.
The payout ratio tells the more dramatic story. It ran positive but elevated through 2024 and 2025, from 53.30% up to 580.49%, before flipping to -148.36% in December 2025 and then to -988.31% as of June 2026.
That negative reading lines up with the GAAP loss per share Pfizer booked in the second quarter, a direct result of the SV and Oxbryta impairments management described on the call, not a shortfall in the cash funding the dividend itself.
Pfizer stock’s yield sits at 6.30% as of the most recent reading, below its 7.91% high but still above its 4.84% low and close to its 6.36% mean. That yield has held in a tight band even as the payout ratio swung from triple-digit positive to quadruple-digit negative, evidence the market is pricing the dividend off cash generation rather than the GAAP figure the impairment distorted.
The open question is whether Pfizer’s payout ratio returns to a conventional positive reading once the SV and Oxbryta charges roll out of the trailing period, or whether further loss-of-exclusivity-related impairments keep distorting it through 2028.
TIKR’s Model Pegs Pfizer Stock’s Target Price at $32, With the Dividend Just One Piece of the Return
TIKR’s mid-case valuation model puts Pfizer stock’s target price at $32 by March 2032, a potential total return of 15% from the current $28 share price, working out to an annualized rate of 3%.
That return profile positions Pfizer stock as a defensive holding rather than a growth trade, a modest annualized gain built from a mix of dividend income and gradual price appreciation rather than a re-rating story.
The model’s reachability rests on the same business picture management laid out on the call: raised full-year revenue guidance to $60.5 billion to $62.5 billion, non-COVID revenue growth of 5% operationally, and a pipeline still positioned for high single-digit revenue growth once the loss-of-exclusivity period ends in 2028.
Should You Invest in Pfizer Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze PFE stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
